نتایج جستجو برای: high dose cytarabine

تعداد نتایج: 2292508  

Journal: :Archives of otolaryngology--head & neck surgery 2002
Hiromi Kojima Minoru Iida Hidemi Miyazaki Tomohiko Koga Hiroshi Moriyama Yoshinobu Manome

BACKGROUND Cytarabine is the most effective agent known for the treatment of acute myeloid leukemia. Its antitumor effect is expressed by combining with DNA during replication and then destroying the DNA chain. However, cytarabine has only limited activity against most solid tumors, including squamous cell carcinoma of the head and neck. The reason for this is thought to be that in cell lines o...

Journal: :Blood 2015
Yasuyuki Arai June Takeda Kazunari Aoki Tadakazu Kondo Satoshi Takahashi Yasushi Onishi Yukiyasu Ozawa Nobuyuki Aotsuka Yasuji Kouzai Hirohisa Nakamae Shuichi Ota Chiaki Nakaseko Hiroki Yamaguchi Koji Kato Yoshiko Atsuta Akiyoshi Takami

Cord blood transplantation (CBT) is an effective therapeutic option for adults with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after the conventional cyclophosphamide and total body irradiation (CY/TBI) regimen, but posttransplant relapse is still of high importance. High-dose cytarabine (HDCA) can be added to CY/TBI for an intensified regimen; however, its additional e...

Journal: :Blood 2008
Beverly J Lange Franklin O Smith James Feusner Dorothy R Barnard Patricia Dinndorf Stephen Feig Nyla A Heerema Carola Arndt Robert J Arceci Nita Seibel Margie Weiman Kathryn Dusenbery Kevin Shannon Sandra Luna-Fineman Robert B Gerbing Todd A Alonzo

CCG-2961 incorporated 3 new agents, idarubicin, fludarabine and interleukin-2, into a phase 3 AML trial using intensive-timing remission induction/consolidation and related donor marrow transplantation or high-dose cytarabine intensification. Among 901 patients under age 21 years, 5-year survival was 52%, and event-free survival was 42%. Survival improved from 44% between 1996 and 1998 to 58% b...

2016
Wilfred Delacruz Robert Setlik Arash Hassantoufighi Shyam Daya Susannah Cooper Dale Selby Alexander Brown

Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of hematologic malignancies which typically respond to standard first-line chemoimmunotherapy regimens. Unfortunately, patients with refractory NHL face a poor prognosis and represent an unmet need for improved therapeutics. We present two cases of refractory CD30+ NHL who responded to novel brentuximab vedotin- (BV-) based regimens. The fi...

2015
M. Lazenby R. Hills A.K. Burnett J. Zabkiewicz

HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for heterogeneous malignancies such as Acute Myeloid Leukemia (AML). Ganetespib is a h...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید